Lilia

Chlormadinone acetate and ethinylestradiol, the active ingredients in Lilia, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and creating cervical mucus changes. GNH USA supplies Lilia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lilia is a combined hormonal contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy. - Pregnancy prevention: provides reliable birth control for women of childbearing potential. - Oral contraception: offers a daily oral regimen to inhibit ovulation and fertilisation. - Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.

Lilia may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of the breasts. - Irregular bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hypertension: new‑onset or worsening high blood pressure. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Lilia, clinicians should evaluate individual risk factors and counsel patients on safety considerations. - Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used. - Avoid in smokers over 35 years: increased risk of cardiovascular events. - Assess history of thromboembolic disorders: risk of clot formation may be elevated. - Monitor blood pressure regularly: may cause or worsen hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Lilia can interact with several medicines that affect hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Strong CYP3A4 inducers (e.g., rifampicin, griseofulvin): can lower hormone levels. - Other estrogen‑containing products (e.g., hormone replacement therapy): may increase estrogen exposure.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., metronidazole): may slightly diminish effectiveness. - Antifungals such as ketoconazole: can increase hormone concentrations. - St. John’s wort herbal supplement: may decrease contraceptive reliability.